Department of Health and Human Services, through National Institutes of Health, awarded L2 Diagnostics LLC of Woodbridge, CT $599,954 under the STTR program (Phase I), with work starting 2025-09-15 and running to 2027-08-31. It is one of 3 SBIR and STTR awards L2 Diagnostics LLC received in the last two years, $1,223,044 in all. Each figure links to the federal record.
The award
| Recipient | L2 Diagnostics LLC (Woodbridge, CT) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase I |
| Amount obligated | $599,954 |
| Period of performance starts | 2025-09-15 |
| Period of performance ends | 2027-08-31 |
| Award number | R41AI195230 (grant, CFDA 93.855) |
| Assistance listing | 93.855, Allergy and Infectious Diseases Research |
| Place of performance | New Haven, South Central Connecticut County, CT |
| Recipient registry id (UEI) | GKA7VH5LFR25 |
Want the whole picture on L2 Diagnostics LLC?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on L2 Diagnostics LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on L2 Diagnostics LLC covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Pfag, a multivalent peptide vaccine against malaria - abstract pfag is our novel malaria vaccine, composed of short synthetic peptides representing specific immunogenic epitopes of the plasmodium falciparum circumsporozo
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-08-28 | Continuation | 000 | $300,000 |
| 2025-09-15 | New | 000 | $299,954 |
Pfag, a multivalent peptide vaccine against malaria - abstract pfag is our novel malaria vaccine, composed of short synthetic peptides representing specific immunogenic epitopes of the plasmodium falciparum circumsporozoite (csp) and anopheles gambiae trio (ag trio) proteins. Our prototype pf ag has yielded outstanding early results, including immunogenicity to target antigens and to achieve sterile immunity in an outbred heterogenous CD-1 mouse model. This Phase I feasibility STTR project aims to (i) optimize the prototype pfag vaccine construct and (ii) conduct efficacy testing to confirm the optimal construct design. Our long-term goal is to develop a novel peptide-based vaccine that can be used alone as a multivalent csp/agtrio vaccine or co-administered with existing pre-erythrocytic vaccines such as rts,s and R21 for a more robust immunological initial or boost response. Our target customers include global health and government organizations calling on developing new tools to eradicate malaria. A peptide-based vaccine's safety, production, and cost profile are favorable for addressing the real-world challenges of deploying a vaccine in malaria-endemic, resource-poor countries, where the current malaria eradication approach is limited by efficacy, cost, and logistics issues.
From the federal award record.
Other SBIR and STTR awards to L2 Diagnostics LLC
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2026-09-21 | Department of Health and Human Services | SBIR Phase I | $323,090 | A novel therapeutic, L2ASOCLE, for treating cutaneous lupus erythematosus (cle) - project (record) |
| 2024-12-01 | Department of Health and Human Services | SBIR Phase I | $300,000 | Novel diagnostic biomarkers discovery and validation for malaria SBIR Phase I (record) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on L2 Diagnostics LLCLook up L2 Diagnostics LLC and see what is on record before you decide.
Get the free SnapshotWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.